HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to
B7-H3, a target wildly expressed on solid tumor cells.
This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety,
pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with
relapsed or refractory osteosarcoma and other sarcomas.